Latest Oncology News

Fox Chase Cancer Center Study Shows That Examining More Lymph Nodes Was Associated With Improved Outcomes for Patients With Colon Cancer

Fox Chase Cancer Center Study Shows That Examining More Lymph Nodes Was Associated With Improved Outcomes for Patients With Colon Cancer

April 4th 2025

Fox Chase Cancer Center

Removing and testing more lymph nodes during surgery was associated with more accurate staging and better survival rates for patients with colon cancer.

Chemotherapy-Free Combos Lead the Way in R/R Follicular Lymphoma

Chemotherapy-Free Combos Lead the Way in R/R Follicular Lymphoma

April 4th 2025

Kyle Doherty

OncologyLive was onsite at the 2024 ASH Annual Meeting to film a Peer Exchange featuring expert commentary on follicular lymphoma.

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL

April 4th 2025

Kyle Doherty

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Caroline Seymour

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD

Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD

April 3rd 2025

Chandler Park, MD, MSc, FACP

Dr Park discusses the core regimens in the current frontline bladder cancer treatment paradigm and ways that this paradigm is expected to evolve.

Latest Oncology Videos

Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center
Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer
Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis
Future Considerations for Treatment Sequencing in B-ALL
Ongoing Research to Watch in Ovarian Cancer in 2025
Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis
Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL
Dr Shore on the Importance of Addressing Gaps in Prostate Cancer Management
Dr Van Gorp on the Role of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting
Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer
PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer
MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer
Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL
Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations
Dr Moertel on the Importance of Managing MEK Inhibitor–Associated Toxicites in NF1-Associated PN
Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL
Dr Herzberg on Notable Ongoing Research in KRAS-Mutated NSCLC
Dr Randall on Survey Results for Frozen Margin Sampling in Soft Tissue Sarcoma Resection
Dr Carles Galceran on the Safety of Darolutamide with ADT and Docetaxel in Older Patients With mHSPC
Dr Merseburger on Real-World Avelumab/Axitinib Discontinuations in Advanced RCC
Dr Kopetz on the Safety of Encorafenib Plus Cetuximab in BRAF V600E+ CRC

All Oncology News

Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer

April 3rd 2025

Kyle Doherty

Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.

Kidney Cancer Awareness Month Spotlights Early Symptom Recognition, Current Challenges, and Key Treatment Advancements

April 3rd 2025

Courtney Flaherty

I. Alex Bowman, MD, underscores how Kidney Cancer Awareness Month enables earlier disease detection, promotes patient education, and drives vital research.

FDA Gives RPDD to NEO100 for Pediatric-Type Diffuse High-Grade Glioma

April 3rd 2025

Ashley Chan

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

April 3rd 2025

Ashling Wahner

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Brain Imaging Plus Virtual Reality Shows Promise for Effectively Managing Cancer Pain

April 3rd 2025

Roswell Park Comprehensive Cancer Center

Roswell Park-led study takes a significant step toward relief without opioid.

Avutometinib/Defactinib Combo Shows Potential in Recurrent Mesonephric Gynecologic Cancer

April 3rd 2025

Jax DiEugenio

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

Survey Identifies Factors Most Important to Fellows When Selecting a Career Path

April 3rd 2025

Kyle Doherty

A cross-sectional study reveals insights on factors hematology and oncology fellows weigh when selecting a career path after fellowship.

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

April 3rd 2025

Chandler Park, MD, MSc, FACP

Drs Park and Koshkin discuss the benefits of enfortumab vedotin in bladder cancer and the potential for more ADCs to join the treatment paradigm.

Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

April 2nd 2025

Courtney Flaherty

Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

April 2nd 2025

Kristi Rosa

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Kristi Rosa

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Jax DiEugenio

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

April 2nd 2025

Ashley Chan

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL

April 2nd 2025

Ashling Wahner

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Chris Ryan

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

See All News

x